MedPath

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Phase 1
Conditions
ipoprotein Disorder
Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Registration Number
CTIS2022-501426-38-00
Lead Sponsor
Eli Lilly & Co.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
255
Inclusion Criteria

Participants must be at least 40 years old and have Lp(a) level =175 nmol/L at screening, Participants if on lipid-lowering drugs or hormone therapy need to be on stable dose for at least 4 weeks prior to screening, A body mass index within the range 18.5 to 40 kilogram/square meter, Males who agree to use highly effective contraception methods or women not of childbearing age

Exclusion Criteria

Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that in the opinion of the investigator, would affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data., Had major surgery within 3 months of day 1, Had coronary, carotid, or peripheral arteria revascularization, stroke, heart attack or chest pain within 3 months of day 1, Have uncontrolled diabetes, Have uncontrolled high blood pressure, Women of childbearing potential

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath